Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Kathryn A. Bylow MD

Associate Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology
Program: Hematology

Member of the Cancer Center


Publications

  • Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). (Atallah E, Bylow K, Troy J, Saber W) Curr Hematol Malig Rep 2014 Mar;9(1):57-65 PMID: 24398726 PMCID: PMC4031643
  • Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. (Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M) Cancer 2014 Mar 1;120(5):692-701 PMID: 24249435
  • The Vulnerable Elders Survey-13 predicts mortality in older adults with later-stage colorectal cancer receiving chemotherapy: a prospective pilot study. (Ramsdale E, Polite B, Hemmerich J, Bylow K, Kindler HL, Mohile S, Dale W) J Am Geriatr Soc 2013 Nov;61(11):2043-4 PMID: 24219208
  • Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case-control study. (Bylow K, Hemmerich J, Mohile SG, Stadler WM, Sajid S, Dale W) Urology 2011 Apr;77(4):934-40 PMID: 21269665 PMCID: PMC3074039
  • WITHDRAWN: Cognitive effects of androgen deprivation therapy in an older cohort of men with prostrate cancer. (Mohile SG et al.) Crit Rev Oncol Hematol 2009 May 14: PMID: 19446466
  • Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study. (Dale W, Hemmerich J, Bylow K, Mohile S, Mullaney M, Stadler WM) J Clin Oncol 2009 Apr 1;27(10):1557-63 PMID: 19255325 PMCID: PMC2738613
  • Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. (Bylow KA, Atkins MB, Posadas EM, Stadler WM, McDermott DF) Clin Genitourin Cancer 2009 Jan;7(1):39-42 PMID: 19213667
  • Management of complications of androgen deprivation therapy in the older man. (Mohile SG, Mustian K, Bylow K, Hall W, Dale W) Crit Rev Oncol Hematol 2009 Jun;70(3):235-55 PMID: 18952456 PMCID: PMC3074615
  • Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy. (Bylow K, Dale W, Mustian K, Stadler WM, Rodin M, Hall W, Lachs M, Mohile SG) Urology 2008 Aug;72(2):422-7 PMID: 18561991 PMCID: PMC3032402
  • Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review. (Bylow K, Mohile SG, Stadler WM, Dale W) Cancer 2007 Dec 15;110(12):2604-13 PMID: 17960609
  • Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. (Ryan CW, Huo D, Bylow K, Demers LM, Stadler WM, Henderson TO, Vogelzang NJ) BJU Int 2007 Jul;100(1):70-5 PMID: 17552955
  • A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. (Mohile SG, Bylow K, Dale W, Dignam J, Martin K, Petrylak DP, Stadler WM, Rodin M) Cancer 2007 Feb 15;109(4):802-10 PMID: 17219443
  • Temporal arteritis: The importance of recognizing senescent changes versus quiescent disease in a temporal artery biopsy. (Bylow KA, Brauner DJ) J Am Geriatr Soc 2006 Dec;54(12):1959-60 PMID: 17198518
  • Last update: 06/03/2014